The US Food and Drug Administration (FDA) said it has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is now resolved.
French drug major Sanofi and the US unit of Israel’s Teva Pharmaceutical Industries have presented new, detailed results from the RELIEVE UCCD Phase IIb study of duvakitug, a human IgG1-λ2 monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback